At a Glance

Other earnings, excluding one-time gains or charges unless noted, include:

* Biogen Inc. said third-quarter profit rose 10% to $68.4 million, or 44 cents a share, a penny better than estimates. Sales rose 12% to $233.7 million, led by an 18% jump in sales of Avonex, the world’s best-selling multiple sclerosis treatment. Avonex accounts for 80% of Biogen’s revenue.

* Rite Aid Corp. said losses from continuing operations more than doubled in its fiscal second quarter to $425 million, or $1.87 a share, from $154.4 million, or 60 cents, a year ago, swollen by debt-related charges, higher interest expense and increased store closings. Revenue rose 6% to $3.4 billion. Sales at stores open at least a year were up 9.9%, boosted by higher prescription sales. Rite Aid shares, which have tumbled 50% since July, fell 81 cents, or 20%, to close at $3.19 on the NYSE.